Clinical Trial Update: Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating furmonertinib 160 mg as first-line therapy for locally advanced or metastatic non-small cell lung cancer with EGFR classical mutations …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING